abiraterone acetate / Generic mfg. - LARVOL DELTA

Memantine Hydrochloride in Prostate Cancer Patients (clinicaltrials.gov) - P2 | N=15 | Not yet recruiting | Sponsor: Ziqi Zhu

New P2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor

EvoPAR-PR02: A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (clinicaltrials.gov) - P3 | N=700 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Preclinical pharmacokinetic and pharmacodynamic study of GS24-B039, a 3-month long-acting abiraterone prodrug (ESMO 2025) - No abstract available

PK/PD data • Preclinical • Oncology

Drug–Drug Interactions in Older Patients Treated with Abiraterone or Enzalutamide for Advanced Prostate Cancer: Results from the ADHERE Prospective Study (Meet-URO Network) (ESMO 2025) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy of niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations identified by tissue vs plasma assay in MAGNITUDE study final analysis (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • HRD

Real-World Comparison of Abiraterone-Based Triplet versus Doublet Therapy in Metastatic High-Volume Hormone-Sensitive Prostate Cancer: A Multicenter Indian Study (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Comparative Effectiveness of Direct Androgen Receptor Inhibitors (ARIs) versus Abiraterone (Androgen Synthesis Inhibitor) in Real-World Patients (pts) in the US with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (ESMO 2025) - No abstract available

Clinical • HEOR • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Real-world Therapeutic Drug Monitoring (TDM) guided food intervention optimizes abiraterone (Abi) treatment in mCRPC (ESMO 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Quality of Life Analysis in Patients with High-Risk Localized Prostate Cancer Receiving Neoadjuvant Pamiparib plus Abiraterone and ADT: A Prospective Study (ESMO 2025) - No abstract available

Clinical • HEOR • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Prognostic value of SLCO2B1 and HSD3B1 polymorphisms in patients with metastatic castration resistant prostate cancer treated with abiraterone: an ancillary analysis of OPTIMABI phase 2 trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • HSD3B1 • SLCO2B1

Real-World Efficacy and Safety of Low-Dose Abiraterone with Food in First-Line Treatment for Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis (ESMO 2025) - No abstract available

Metastases • Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Real-world prostate-specific antigen (PSA) response with darolutamide or abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) triplet therapy (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Low-Dose versus Standard-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer Post-Docetaxel: A Randomized Controlled Trial Protocol (DUMONT Trial) (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Olaparib Plus Abiraterone in HRR-Mutated Metastatic Hormone-Sensitive Prostate Cancer (ESMO 2025) - No abstract available

Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Two-year Outcomes in Very High-Risk Localized Prostate Cancer Following Neoadjuvant Therapy with Poly(ADP-ribose) Polymerase Inhibitors and Abiraterone: A Pooled Post-Hoc Analysis of Two Prospective Trials (ESMO 2025) - No abstract available

Clinical • Retrospective data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Bone Fractures and Prior Abiraterone Use in Men Treated with Radium-223 and Enzalutamide Combination for Castration Resistant Prostate Cancer (CRPC) with Bone Metastases(m): A Real-World Observational Study (ESMO 2025) - No abstract available

Clinical • Observational data • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281 (ESMO 2025) - No abstract available

Clinical • Metastases • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN

Establishing clinically relevant dissolution specifications for prodrug bioequivalence risk assessment: Integration of a dissolution/permeation system with physiologically based biopharmaceutics modeling in abiraterone acetate. (PubMed, Eur J Pharm Biopharm) - "This study demonstrates that combining biorelevant dissolution with mechanistic modelling mitigates BE risks for high-variability prodrugs. This single-phase approach offers a scalable and physiologically aligned strategy for guiding the generic development of complex formulations with food-dependent absorption variability."

Journal

A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer. (PubMed, J Chemother) - "The PK profile was consistent with non-Japanese patients, with no PK drug-drug interactions detected. The study confirms that the global RP2D of abemaciclib is suitable for Japanese patients with mCRPC treated with abiraterone and prednisolone."

Journal • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

CHAARTED2: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (clinicaltrials.gov) - P2 | N=223 | Active, not recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial primary completion date: Sep 2025 ➔ Mar 2026

Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer (clinicaltrials.gov) - P1 | N=245 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=176 ➔ 245

Enrollment change • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer (clinicaltrials.gov) - P=N/A | N=20 | Enrolling by invitation | Sponsor: Zhujiang Hospital

New trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer. (PubMed, Front Oncol) - "Combining enzalutamide with docetaxel is more effective than docetaxel alone for treating mCRPC after abiraterone and enzalutamide, providing better PSA-PFS and improved metastasis outcomes, along with better pain relief. Though the combination resulted in more adverse effects, no severe reactions (Grade 3 or higher) were observed, indicating good tolerability and clinical potential."

Journal • Monotherapy • Back Pain • Cardiovascular • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hepatology • Hypertension • Liver Failure • Lumbar Back Pain • Oncology • Pain • Prostate Cancer • Solid Tumor • Urology

QUEST: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=136 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Phase classification: P1/2 ➔ P2

Phase classification • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CTCs